BiotechTube

Alglucosidase Alfa + Methotrexate + Rituximab

ApprovedCompleted
0 watching 0 views this week🔥 Hot
84
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Pompe Disease

Conditions

Pompe Disease, Glycogen Storage Disease Type II

Trial Timeline

Oct 1, 2009 → Mar 1, 2013

NCT ID
NCT00701129

About Alglucosidase Alfa + Methotrexate + Rituximab

Alglucosidase Alfa + Methotrexate + Rituximab is a approved stage product being developed by Sanofi for Pompe Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00701129. Target conditions include Pompe Disease, Glycogen Storage Disease Type II.

Hype Score Breakdown

Clinical
30
Activity
20
Company
9
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT00701129ApprovedCompleted

Competing Products

20 competing products in Pompe Disease

See all competitors
ProductCompanyStageHype Score
S-606001 + PlaceboShionogiPhase 2
52
alglucosidase alfaSanofiApproved
84
GZ402666SanofiPhase 1
32
alglucosidase alfa + PlaceboSanofiPhase 3
76
alglucosidase alfaSanofiApproved
84
glucosidase alfaSanofiPre-clinical
22
Alglucosidase alfaSanofiApproved
84
Avalglucosidase AlfaSanofiPhase 2
51
alglucosidase alfaSanofiApproved
84
MyozymeSanofiPhase 3
76
alglucosidase alfaSanofiApproved
84
alglucosidase alfaSanofiPre-clinical
22
Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829)SanofiPhase 3
76
Myozyme® (alglucosidase alfa) + Myozyme® (alglucosidase alfa)SanofiApproved
84
ALGLUCOSIDASE ALFASanofiApproved
84
alglucosidase alfa + alglucosidase alfaSanofiApproved
84
Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829)SanofiPhase 2
51
MyozymeSanofiPhase 2
51
MyozymeSanofiPhase 2
51
recombinant human acid alpha-glucosidase (rhGAA)SanofiPhase 2
51

Other Products from Sanofi

Adacel®Approved
84
LACTIC ACID(ND)Approved
84
DupilumabApproved
84
glatiramer acetateApproved
84
INSULIN GLULISINE + INSULIN GLARGINEApproved
84